EyePoint Pharmaceuticals, Inc.·4

Sep 5, 4:02 PM ET

Hassan Fred 4

4 · EyePoint Pharmaceuticals, Inc. · Filed Sep 5, 2024

Insider Transaction Report

Form 4
Period: 2024-09-03
Hassan Fred
Director
Transactions
  • Award

    Stock Options (Right to buy)

    2024-09-03+60,00060,000 total
    Exercise: $8.16Exp: 2034-09-03Common Stock (60,000 underlying)
Footnotes (1)
  • [F1]The option becomes exercisable in three ratable annual installments beginning on September 3, 2025.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT